{"nctId":"NCT01904149","briefTitle":"Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride","startDateStruct":{"date":"2013-05"},"conditions":["Acute Pain"],"count":606,"armGroups":[{"label":"DKP/TRAM followed by DKP/TRAM","type":"EXPERIMENTAL","interventionNames":["Drug: Dexketoprofen/Tramadol-single dose","Drug: Dexketoprofen/Tramadol-multiple doses"]},{"label":"DKP followed by DKP","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dexketoprofen-single dose","Drug: Dexketoprofen-multiple doses"]},{"label":"TRAM followed by TRAM","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tramadol-single dose","Drug: Tramadol-multiple doses"]},{"label":"Placebo followed by DKP/TRAM","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Dexketoprofen/Tramadol-multiple doses"]},{"label":"Placebo followed by DKP","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Dexketoprofen-multiple doses"]},{"label":"Placebo followed by TRAM","type":"OTHER","interventionNames":["Drug: Placebo","Drug: Tramadol-multiple doses"]}],"interventions":[{"name":"Placebo","otherNames":[]},{"name":"Dexketoprofen-single dose","otherNames":[]},{"name":"Tramadol-single dose","otherNames":[]},{"name":"Dexketoprofen/Tramadol-single dose","otherNames":[]},{"name":"Dexketoprofen-multiple doses","otherNames":[]},{"name":"Tramadol-multiple doses","otherNames":[]},{"name":"Dexketoprofen/Tramadol-multiple doses","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female patients aged 18 to 75 years.\n* Scheduled to undergo a total or subtotal abdominal hysterectomy (with or without salpingo-oophorectomy) for benign conditions.\n* Patients experiencing pain at rest of at least moderate intensity the day after surgery.\n\nExclusion Criteria:\n\n* Patients not suitable for study treatments and rescue medication (RM) or those for whom non-steroidal anti-inflammatory drugs (NSAIDs), opioids, acetyl salicylic acid, pyrazolones or pyrazolidines are contraindicated.\n* Patients with clinically significant abnormalities in vital signs, safety laboratory tests and 12-lead ECG at screening.\n* Patients with history of any illness or condition that might pose a risk to the patient or confound the efficacy and safety study results.\n* Patients using and not suitable to withdraw analgesics other than those specified in the protocol.\n* Patients using and not suitable for withdrawing any of the prohibited medication specified in the protocol.\n* Breastfeeding women.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"SPID8 (Sum of Pain Intensity Differences Over 8 Hours)","description":"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 8 hour period. PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured at 0.5h, 1h, 1.5h, 2h, 3h, 4h, 6h, and 8h after the first dose. A higher value in SPID indicates greater pain relief.\n\nThe analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"241.8","spread":"139.06"},{"groupId":"OG001","value":"184.5","spread":"139.23"},{"groupId":"OG002","value":"157.3","spread":"150.89"},{"groupId":"OG003","value":"117.0","spread":"121.80"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders According to 50% Max TOTPAR (Total Pain Relief)","description":"Percentage of responders over 8 hours after first dose, according to the 50% maximum total pain relief rule: maximum TOTPAR calculated as the theoretical maximum weighted sum of PAR-VRS (Pain Relief - Verbal Rating Scale: pain relief 0=none, 4=complete) scores.\n\nThe analysis was performed combining all randomization arms including placebo into one group, which resulted in the following 4 analysis groups: DKP/TRAM, DEXKETOPROFEN, TRAMADOL, and Placebo.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.8","spread":null},{"groupId":"OG001","value":"47.7","spread":null},{"groupId":"OG002","value":"44.0","spread":null},{"groupId":"OG003","value":"30.7","spread":null}]}]}]},{"type":"SECONDARY","title":"SPID48 (Sum of Pain Intensity Differences Over 48 Hours of the Multiple-dose Phase)","description":"Sum of Pain Intensity Differences calculated as the weighted sum of the PI-VAS differences over 48 hours of the multiple-dose phase.\n\nPI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale (0=no pain to 100=worst pain imaginable) which was measured every two hours over the first 48 hours of the multiple-dose phase. A higher value in SPID indicates greater pain relief.\n\nThe analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2273.0","spread":"864.03"},{"groupId":"OG001","value":"1965.2","spread":"912.19"},{"groupId":"OG002","value":"2035.0","spread":"919.49"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders According to PI-VAS (Pain Intensity - Visual Analogue Scale)","description":"Percentage of responders; response defined as achievement a mean pain intensity, PI-VAS \\< 40 mm (PI-VAS corresponds to the pain intensity measured by a 0-100 visual analogue scale, 0=no pain to 100=worst pain imaginable), over 48 hours of the multiple-dose phase.\n\nThe analysis was performed combining all randomization arms including the same active treatment, which resulted in the following 3 analysis groups: DKP/TRAM, DEXKETOPROFEN, and TRAMADOL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null},{"groupId":"OG001","value":"82.7","spread":null},{"groupId":"OG002","value":"88.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":151},"commonTop":["Nausea","Platelet count increased","Vomiting","Constipation","Blood lactate dehydrogenase increased"]}}}